Quinapril and blood lipids.
To assess the effects of angiotensin-converting enzyme inhibition with quinapril on blood lipid profile, serum total cholesterol and triglycerides, together with high-density and low-density lipoprotein cholesterol were analysed in 23 hypertensive patients receiving either placebo (7 patients) or quinapril hydrochloride (16 patients). After 12 weeks of therapy there were no significant changes in blood lipids in either group. No unfavourable changes in blood lipid profile were observed even after 1 year of therapy with quinapril hydrochloride in 13 patients.
Koskinen
P
P
First Department of Medicine, University Central Hospital, Helsinki, Finland.
Manninen
V
V
Eisalo
A
A
D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D000077583:Quinapril; D044005:Tetrahydroisoquinolines
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007546:Isoquinolines; D008055:Lipids; D044005:Tetrahydroisoquinolines; D000077583:Quinapril